Company profile
Unleash Therapeutics
Developing a clinical-stage immunotherapy for canine osteosarcoma.
- Industry
- Biotechnology Research
- Employees
- 2
- Headquarters
- San Francisco, CA
- Founded
- 2021
- LinkedIn followers
- 27
- Office locations
- 1
Unleash Therapeutics company summary
Unleash Therapeutics is a company in the Biotechnology Research industry, headquartered in San Francisco, CA, founded in 2021. On LinkedIn the company has around 2 employees and 27 followers.
What technology does Unleash Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Unleash Therapeutics
Unleash Therapeutics is a single-asset animal health company developing a dual-action immunotherapy for canine osteosarcoma — one of the most common and lethal cancers in dogs. Our novel checkpoint inhibitor (CD200AR-L) is based on research from the University of Minnesota. In partnership with Ardent Animal Health, the checkpoint inhibitor is being combined with an autologous cancer vaccine (K9-ACV) in a USDA-regulated, multi-center clinical trial. Recruitment is now complete. The company was founded in 2021 by Dr. Elizabeth Iorns and Dan Knox, who are also the co-founders of Familiar, a companion animal therapeutics company building a broad pipeline of modern medicines for pets.
Where is Unleash Therapeutics located?
Unleash Therapeutics lists 1 location.
Compare companies similar to Unleash Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Unleash Therapeutics unleashtx.com | Biotechnology Research | 2 | 2021 | San Francisco, CA |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Unleash Therapeutics
What does Unleash Therapeutics do?
Unleash Therapeutics is a single-asset animal health company developing a dual-action immunotherapy for canine osteosarcoma — one of the most common and lethal cancers in dogs. Our novel checkpoint inhibitor (CD200AR-L) is based on research from the University of Minnesota. In partnership with Ardent Animal Health, the checkpoint inhibitor is being combined with an autologous cancer vaccine (K9-ACV) in a USDA-regulated, multi-center clinical trial. Recruitment is now complete. The company was founded in 2021 by Dr. Elizabeth Iorns and Dan Knox, who are also the co-founders of Familiar, a companion animal therapeutics company building a broad pipeline of modern medicines for pets.
How many employees does Unleash Therapeutics have?
Unleash Therapeutics has around 2 employees on LinkedIn.
Where is Unleash Therapeutics headquartered?
Unleash Therapeutics is headquartered in San Francisco, CA.
When was Unleash Therapeutics founded?
Unleash Therapeutics was founded in 2021.
Build a lead list from companies like Unleash Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.